The latest headlines across every section, pulled from official and open-access sources.
With the mandatory Ambulatory Specialty Model (ASM) for Heart Failure (HF) slated to begin Jan. 1, 2027, the ACC is prioritizing member awareness and education, while pressing the Centers for Medicare and Medicaid Services (CMS) to address key issues with the model's design and requirements.
An ACC analysis of the preliminary participant list for the Ambulatory Specialty Model (ASM) for Heart Failure found that up to 20% of selected cardiologists may be incorrectly classified under the specialty cardiovascular disease/cardiology.
In this episode, Chief Innovation Officer Dr. Ami Bhatt and Dr. Ankeet Bhatt explore the impact of large language models (LLM) on cardiovascular care today.
Looking to spark an antibody-like revolution for RNA interference medicines, City Therapeutics has landed a nearly $100 million series B to fund a clinical push and power further development of its foundational platform.
A Dexcom continuous glucose monitor helped adults with type 2 diabetes not using insulin improve blood sugar control in a randomized trial, adding new fuel to the industry’s push to bring CGMs into broader primary care use.
ResMed has closed its $340 million acquisition of Noctrix Health, picking up a wearable neuromodulation device that pushes the sleep tech giant beyond its core sleep apnea and respiratory care businesses.
Treeline Biosciences, an under-the-radar cancer company that has raised more than $1 billion since its 2021 founding, is looking to step into the spotlight of the public market. Treeline has announced plans to merge with omics outfit Standard BioTools and secure a listing on the Nasdaq.
Johnson & Johnson has paid $1 billion upfront to buy itself a degrader antibody conjugate platform via the acquisition of Firefly Bio.
Incyte has struck a deal to buy a Star Therapeutics subsidiary for $1.25 billion upfront. The takeover, the biggest bet of Bill Meury’s time as CEO, covers a late-phase bleeding disorder drug candidate that could support Incyte’s ambition to grow through the loss of patent protection for Jakafi in 2028.
GSK’s latest hepatology partnership is posing a less-asked question—how do you encourage the regression of patients’ liver fibrosis?
RevHealth CEO Ben Beckley shares how integrated teams are helping biopharma organizations align strategy, break down silos and drive stronger commercial impact.
SK pharmteco CEO Joerg Ahlgrimm discusses complexity, global pressure and drug development speed.
AI is accelerating discovery, but only when paired with expert insight and trusted data. Hear how leaders are rethinking decision-making in biopharma.
With unmet need still high in AML, new approaches are exploring whether engaging immune responses could help improve long-term disease control.
Unlearn founder and head of AI, Aaron Smith, on how digital twins are moving from trial simulation into the full chain of decisions sponsors make — and what regulators need to see along the way.
Strategy matters—but execution separates leaders. Hear how top biopharma teams translate strategy into results.
PhaseV CEO Raviv Pryluk explains how AI is reshaping trial design and execution.
Capital is tighter and expectations are higher. Hear how biotech leaders must rethink value, evidence and deal readiness in 2026.
Regulatory shifts, tight capital and volatile IPO windows are reshaping biopharma strategy. Hear how leaders are adapting.
Tighter capital, higher expectations and evolving regulatory frameworks are reshaping drug development strategy. Parexel leaders explain how companies are adapting.
Discover how these trailblazers are accelerating breakthroughs, forging impactful partnerships, and redefining what’s possible in life sciences. Access the exclusive interviews below to get inspired and stay ahead of the curve.
City of Hope built a national trials engine to move oncology innovation faster, wider and with the scale sponsors need.
Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly’s Jaypirca in a phase 3 trial.
A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.